- Home
- OFLX vs RIGL Comparison
OFLX vs RIGL Comparison
Compare OFLX & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OFLX
- RIGL
- Stock Information
- Founded
- OFLX 1975
- RIGL 1996
- Country
- OFLX United States
- RIGL United States
- Employees
- OFLX N/A
- RIGL N/A
- Industry
- OFLX Industrial Specialties
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- OFLX Industrials
- RIGL Health Care
- Exchange
- OFLX Nasdaq
- RIGL Nasdaq
- Market Cap
- OFLX 366.4M
- RIGL 335.5M
- IPO Year
- OFLX 2005
- RIGL 2000
- Fundamental
- Price
- OFLX $30.43
- RIGL $28.20
- Analyst Decision
- OFLX
- RIGL Buy
- Analyst Count
- OFLX 0
- RIGL 5
- Target Price
- OFLX N/A
- RIGL $38.20
- AVG Volume (30 Days)
- OFLX 21.1K
- RIGL 644.0K
- Earning Date
- OFLX 10-29-2025
- RIGL 11-06-2025
- Dividend Yield
- OFLX 4.58%
- RIGL N/A
- EPS Growth
- OFLX N/A
- RIGL N/A
- EPS
- OFLX 1.69
- RIGL 5.43
- Revenue
- OFLX $100,700,000.00
- RIGL $267,921,000.00
- Revenue This Year
- OFLX N/A
- RIGL $59.93
- Revenue Next Year
- OFLX N/A
- RIGL N/A
- P/E Ratio
- OFLX $18.29
- RIGL $5.42
- Revenue Growth
- OFLX N/A
- RIGL 105.62
- 52 Week Low
- OFLX $28.12
- RIGL $13.57
- 52 Week High
- OFLX $57.81
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- OFLX 28.86
- RIGL 36.60
- Support Level
- OFLX $30.24
- RIGL $27.75
- Resistance Level
- OFLX $31.11
- RIGL $29.46
- Average True Range (ATR)
- OFLX 1.01
- RIGL 1.53
- MACD
- OFLX -0.33
- RIGL -0.30
- Stochastic Oscillator
- OFLX 0.00
- RIGL 15.24
About OFLX Omega Flex Inc.
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.